Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10155577 | 0.87 | MEN1 (0.54) | HTR1ADRD2HRH4HTR3AKMT2A | |
| SCHEMBL12903094 | 0.83 | KMT2A (0.55) | HRH4HTR3AKMT2A | |
| SCHEMBL22924659 | 0.83 | KMT2A (0.55) | HRH4HTR3AKMT2A | |
| SCHEMBL12490124 | 0.81 | SMN1; SMN2 (0.63) | KMT2A | |
| SCHEMBL778158 | 0.81 | HRH1 (0.47) | KMT2A | |
| SCHEMBL25724011 | 0.81 | HRH4 (0.59) | HTR1ADRD2HRH4HTR3AKMT2A | |
| SCHEMBL2259115 | 0.78 | HTR2A (0.52) | HTR1ADRD2KMT2A | |
| SCHEMBL3026440 | 0.76 | L3MBTL1 (0.45) | KMT2A | |
| SCHEMBL22661439 | 0.75 | HRH4 (0.61) | HTR1ADRD2HRH4HTR3AKMT2A | |
| SCHEMBL22603853 | 0.75 | HRH4 (0.61) | HTR1ADRD2HRH4HTR3AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097378-B1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-7994317-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100069391-A1 | Novel sEH Inhibitors and Their Use | SMITHKLINE BEECHAM CORPORATION | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069391-A1 | Novel sEH Inhibitors and Their Use | FAH, NCEH1, SELENOI | HTR1A 4126/4885DRD2 4745/4885HRH4 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.